Chemistry:SR8278
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H19NO3S2 |
| Molar mass | 361.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SR-8278 is an experimental drug that was developed as an antagonist of Rev-ErbAα.[1] It has been used to demonstrate potential applications of Rev-ErbAα antagonists in the treatment of conditions such as Duchenne muscular dystrophy and Alzheimer's disease.[2][3]
See also
References
- ↑ "Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB". ACS Chemical Biology 6 (2): 131–4. February 2011. doi:10.1021/cb1002575. PMID 21043485.
- ↑ "Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle". Scientific Reports 7 (1): 17142. December 2017. doi:10.1038/s41598-017-17496-7. PMID 29215066. Bibcode: 2017NatSR...717142W.
- ↑ "Inhibition of REV-ERBs stimulates microglial amyloid-beta clearance and reduces amyloid plaque deposition in the 5XFAD mouse model of Alzheimer's disease". Aging Cell 19 (2): e13078. February 2020. doi:10.1111/acel.13078. PMID 31800167.
 |  |
